iovance
biotherapeutics
present
upcoming
october
conferences
san
carlos
globe
newswire
iovance
biotherapeutics
nasdaq
iova
biotechnology
company
developing
novel
cancer
immunotherapies
today
announced
company
plans
present
following
conferences
jefferies
cell
therapy
summit
virtual
october
date
time
tuesday
edt
webcast
live
archived
webcast
presentation
available
investors
section
iovance
website
http
alliance
regenerative
medicine
arm
meeting
mesa
virtual
october
date
time
presentation
available
demand
beginning
http
live
archived
webcast
presentation
available
investors
section
iovance
website
http
iovance
biotherapeutics
iovance
biotherapeutics
aims
improve
patient
care
making
immunotherapies
broadly
accessible
treatment
patients
solid
tumors
blood
cancers
tumor
infiltrating
lymphocyte
til
therapy
uses
patient
immune
cells
attack
cancer
til
cells
extracted
patient
tumor
tissue
expanded
proprietary
process
infused
back
patient
infusion
til
reach
tumor
tissue
attack
tumor
cells
company
completed
dosing
pivotal
study
patients
metastatic
melanoma
currently
conducting
pivotal
study
patients
advanced
cervical
cancer
addition
company
til
therapy
investigated
treatment
patients
locally
advanced
recurrent
metastatic
cancers
including
head
neck
cell
lung
cancer
clinical
study
investigate
iovance
cell
therapy
blood
cancers
called
peripheral
blood
lymphocyte
pbl
therapy
open
enrollment
information
please
visit
statements
certain
matters
discussed
press
release
statements
iovance
biotherapeutics
hereinafter
referred
company
us
within
meaning
private
securities
litigation
reform
act
pslra
written
oral
statements
made
press
release
filings
securities
exchange
commission
sec
reports
stockholders
meetings
investors
analysts
statements
historical
fact
statements
intended
covered
safe
harbor
statements
provided
pslra
without
limiting
foregoing
may
cases
use
terms
predicts
believes
potential
continue
estimates
anticipates
expects
plans
intends
forecast
guidance
outlook
may
could
might
words
convey
uncertainty
future
events
outcomes
intended
identify
statements
statements
include
limited
statements
regarding
success
timing
projected
enrollment
manufacturing
production
capabilities
cost
ongoing
clinical
trials
anticipated
clinical
trials
current
product
candidates
including
trials
europe
statements
regarding
timing
initiation
completion
trials
strength
company
product
pipeline
guidance
provided
company
future
cash
cash
equivalents
short
term
investments
restricted
cash
balances
forecasted
operating
expenses
statements
involve
risks
uncertainties
factors
may
cause
actual
results
levels
activity
performance
achievements
developments
materially
different
expressed
implied
statements
including
without
limitation
following
substantial
known
unknown
risks
uncertainties
inherent
company
business
pandemic
may
adverse
effect
company
clinical
trials
including
potential
slower
patient
recruitment
inability
clinical
trial
sites
collect
data
inability
company
contract
research
organizations
monitor
patients
well
food
drug
administration
fda
availability
due
competing
priorities
ability
achieve
profitability
successfully
commercialize
products
alone
third
parties
well
history
operating
losses
expectations
continue
incur
significant
operating
losses
limited
operating
history
current
line
business
makes
difficult
evaluate
prospects
business
plan
likelihood
successfully
implementing
business
plan
risks
related
timing
ability
successfully
develop
submit
obtain
maintain
fda
regulatory
authority
approval
action
respect
product
candidates
including
respect
lifileucel
treatment
metastatic
melanoma
reaching
agreement
fda
appropriate
potency
assay
timing
submit
biologics
licensing
application
bla
fda
ability
successfully
commercialize
product
candidates
obtain
fda
approval
limited
history
conducting
clinical
trials
future
profitability
substantially
dependent
need
rely
third
parties
including
contract
research
organizations
contract
manufacturing
organizations
consultants
connection
conduct
supervision
monitoring
clinical
trials
product
candidates
preliminary
interim
clinical
results
may
include
efficacy
safety
results
ongoing
phase
studies
may
reflected
final
analyses
ongoing
clinical
trials
subgroups
within
trials
risk
slower
rate
enrollment
may
delay
company
clinical
trial
timelines
otherwise
adversely
impact
clinical
development
activities
risk
enrollment
may
need
adjusted
company
trials
cohorts
within
trials
based
fda
regulatory
agency
input
new
version
protocol
defines
patient
population
include
advanced
patients
company
cervical
cancer
trial
may
adverse
effect
results
reported
date
risk
results
obtained
ongoing
clinical
trials
may
indicative
results
obtained
future
clinical
trials
data
within
trials
may
supportive
product
approval
including
later
developments
fda
may
inconsistent
already
completed
fda
meetings
risk
fda
may
agree
approach
expand
cervical
cancer
trial
include
cohort
trial
risk
changes
patient
populations
may
result
changes
preliminary
clinical
results
company
ability
inability
address
fda
regulatory
authority
requirements
relating
clinical
programs
registrational
plans
requirements
including
limited
clinical
safety
manufacturing
control
requirements
risk
regulatory
authorities
may
potentially
delay
timing
fda
regulatory
approval
action
respect
product
candidates
may
required
conduct
additional
clinical
trials
modify
ongoing
future
clinical
trials
based
feedback
fda
regulatory
authorities
risk
company
interpretation
results
clinical
trials
communications
fda
may
differ
interpretation
results
communications
fda
ability
obtain
maintain
intellectual
property
rights
related
product
pipeline
ability
successfully
implement
research
development
programs
collaborations
acceptance
market
product
candidates
potential
reimbursement
payors
approved
ability
obtain
tax
incentives
credits
risk
existing
net
operating
loss
carryforwards
research
tax
credits
may
expire
otherwise
limited
use
success
manufacturing
license
development
agreements
risks
related
company
ability
maintain
benefit
accelerated
fda
review
designations
including
breakthrough
therapy
designation
regenerative
medicine
advanced
therapy
designation
may
result
faster
development
process
review
company
product
candidates
may
later
rescinded
fda
assure
approval
product
candidates
fda
ability
company
obtain
fda
approval
time
benefit
commercial
opportunities
ability
inability
company
manufacture
therapies
using
third
party
manufacturers
facility
may
adversely
affect
company
potential
commercial
launch
results
clinical
trials
collaborators
using
different
manufacturing
processes
may
reflected
company
sponsored
trials
dependence
additional
financing
fund
operations
complete
development
commercialization
product
candidates
risks
raising
additional
capital
may
restrict
operations
require
us
relinquish
rights
technologies
product
candidates
risk
additional
expenses
may
decrease
estimated
cash
balances
increase
estimated
capital
requirements
factors
may
material
adverse
effect
company
business
clinical
development
including
general
economic
conditions
pandemic
regulatory
developments
within
company
control
contacts
iovance
biotherapeutics
inc
sara
pellegrino
irc
vice
president
investor
relations
public
relations
ext
solebury
trout
annie
chang
investors
achang
chad
rubin
investors
crubin
rich
allan
media
rallan
